Abstract:IgA nephropathy (IgAN) is the most common primary glomerulonephritis, frequently leading to end-stage renal disease, as there is no disease-specific therapy. IgAN is diagnosed from pathological assessment of a renal biopsy specimen based on predominant or codominant IgA-containing immunodeposits, usually with complement C3 co-deposits and with variable presence of IgG and/or IgM. The IgA in these renal deposits is galactose-deficient IgA1, with less than a full complement of galactose residues on the O-glycans in the hinge region of the heavy chains. Research from the past decade led to the definition of IgAN as an autoimmune disease with a multi-hit pathogenetic process with contributing genetic and environmental components. In this process, circulating galactose-deficient IgA1 (autoantigen) is bound by antiglycan IgG or IgA (autoantibodies) to form immune complexes. Some of these circulating complexes deposit in glomeruli, and thereby activate mesangial cells and induce renal injury through cellular proliferation and overproduction of extracellular matrix components and cytokines/chemokines. Glycosylation pathways associated with production of the autoantigen and the unique characteristics of the corresponding autoantibodies in patients with IgAN have been uncovered. Complement likely plays a significant role in the formation and the nephritogenic activities of these complexes. Complement activation is mediated through the alternative and lectin pathways and probably occurs systemically on IgA1-containing circulating immune complexes as well as locally in glomeruli. Incidence of IgAN varies greatly by geographical location; the disease is rare in central Africa but accounts for up to 40% of native-kidney biopsies in eastern Asia. Some of this variation may be explained by genetically determined influences on the pathogenesis of the disease. Genome-wide association studies to date have identified several loci associated with IgAN. Some of these loci are associated with the increased prevalence of IgAN, whereas others, such as deletion of complement factor H-related genes 1 and 3, are protective against the disease. Understanding the molecular mechanisms and genetic and biochemical factors involved in formation and activities of pathogenic IgA1-containing immune complexes will enable the development of future disease-specific therapies as well as identification of non-invasive disease-specific biomarkers.

Mass spectrometry-based circulating IgA1 complexes screening driven identification of IgA-alpha-1-microglobulin complex in IgA nephropathy.

Mass spectrometry-based screening identifies circulating immunoglobulinA–α1-microglobulin complex as potential biomarker in immunoglobulin A nephropathy

Integrated Proteomics and Metabolomics to Study IgA Nephropathy on Early Stage and Identification of Biomarkers

Clinical and Pathology Features of IgA Nephropathy with Active Tubular Interstitial Lesions

Identification and characterization of circulating immune complexes in IgA nephropathy

Urinary Proteome Analysis by Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry with Magnetic Beads for Identifying the Pathologic Presentation of Clinical Early Iga Nephropathy

Serum Proteomic Analysis by Nanoflow LC-MS/MS-Based Proteomics in IgA Chronic Kidney Disease

IgA-containing immune complexes in the urine of IgA nephropathy patients

Poly-IgA Complexes and Disease Severity in IgA Nephropathy

Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy

The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy

Urinary complement proteins in IgA nephropathy progression from a relative quantitative proteomic analysis

Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy

Unveiling biomarkers and therapeutic targets in IgA nephropathy through large-scale blood transcriptome analysis

Characterization of patients with IgA nephropathy with and without associated minimal change disease

Endothelial Injury by Circulating IgA1 Complex Through the Activation of Mesangial Cells in IgA Nephropathy.

Microbiome and metabolome analysis to clarify the interaction between the urine microbiota and serum metabolites in Chinese patients with immunoglobulin A nephropathy

IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy

Serum Soluble CD89-IgA Complexes Are Elevated in IgA Nephropathy without Immunosuppressant History

Proteomic profiling of IgA nephropathy reveals distinct molecular prognostic subtypes